Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes

BACKGROUND: The aim was to assess patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) treated with filgotinib during two phase 2b, 24-week, randomized, placebo-controlled studies. METHODS: Patients with moderate-to-severe active RA and an inadequate response to methotrexate (...

Descripción completa

Detalles Bibliográficos
Autores principales: Genovese, Mark, Westhovens, Rene, Meuleners, Luc, Van der Aa, Annegret, Harrison, Pille, Tasset, Chantal, Kavanaugh, Arthur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865354/
https://www.ncbi.nlm.nih.gov/pubmed/29566740
http://dx.doi.org/10.1186/s13075-018-1541-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865354/
https://www.ncbi.nlm.nih.gov/pubmed/29566740
http://dx.doi.org/10.1186/s13075-018-1541-z

Ejemplares similares